surmount-1 trial tirzepatide weight loss non-diabetic after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 Read now: The SURPASS-EARLY trial

In 2020, the FDA approved the use of Saxenda for treating obesity in children as young as 12 years old

No studies have confirmed a link between GLP-1 medications and thyroid tumors in humans, but if you have a history of family thyroid cancer, you may want to discuss taking a GLP-1 with your primary care provider

The medication is administered as a once-weekly subcutaneous injection, starting with a low dose (0.25 mg) that is gradually increased over 16 weeks to the maintenance dose of 2.4 mg

Melanotan-2 compound is studied within cognitive research peptides and is commonly associated with neuroendocrine signaling molecules